1. Home
  2. UTHR

UTHR

United Therapeutics Corporation

Logo United Therapeutics Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Founded: 1996 Country:
United States
United States
Employees: N/A City: SILVER SPRING
Market Cap: 11.2B IPO Year: 1999
Target Price: $292.67 AVG Volume (30 days): 453.1K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 19.81 EPS Growth: 32.07
52 Week Low/High: $204.44 - $261.54 Next Earning Date: 05-01-2024
Revenue: $2,327,500,000 Revenue Growth: 20.20%
Revenue Growth (this year): 18.32% Revenue Growth (next year): 4.72%

Share on Social Networks: